Study of Tepotinib Combined With Cetuximab in Participants With Left-Sided RAS/BRAF Wild Type Metastatic Colorectal Cancer (PERSPECTIVE)

Stopped The study was terminated early due to operational challenges identifying suitable participants for screening in the study.

Conditions

• Colorectal Neoplasms

Interventions

• DRUG: Tepotinib
• BIOLOGICAL: Cetuximab

Sponsor

EMD Serono Research & Development Institute, Inc.

Collaborators

• [object Object]